| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14.1% | +15.8% | $324M | $45.3M | 4.91M | +16.3% | FMR LLC | 30 Sep 2025 |
| AI DMI LLC | 8% | -25.5% | $199M | -$49.2M | 3.02M | -19.8% | AI DMI LLC | 20 Oct 2025 |
| ORBIMED ADVISORS LLC | 4.5% | $73.4M | 1.56M | ORBIMED ADVISORS LLC | 10 Mar 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 4.1% | -38.6% | $80M | -$50.9M | 1.43M | -38.9% | Wellington Management Group LLP | 30 Jun 2025 |
| Paradigm Biocapital Advisors LP | 3.5% | $57.1M | 1.21M | Paradigm BioCapital Advisors LP | 31 Mar 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 3% | $57.3M | 1.03M | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2025 | |||
| Bain Capital Life Sciences Opportunities III, LP | 3.3% | $46.4M | 984K | Bain Capital Life Sciences Opportunities III, LP | 31 Dec 2024 | |||
| Atlas Venture Fund X, L.P. | 2.2% | -30% | $73.5M | -$24.5M | 813K | -25% | Atlas Venture Fund X, L.P. | 12 Dec 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 34.2M | $2.26B | +$16.1M | $66.08 | 163 |
| 2025 Q2 | 34.1M | $1.8B | +$52.4M | $52.96 | 148 |
| 2025 Q1 | 33.2M | $1.65B | +$314M | $49.64 | 155 |
| 2024 Q4 | 26.6M | $1.68B | -$53.2M | $63.40 | 151 |
| 2024 Q3 | 27.3M | $1.34B | -$26.6M | $49.14 | 130 |
| 2024 Q2 | 27.6M | $1.24B | +$213M | $45.07 | 119 |
| 2024 Q1 | 22.2M | $1.38B | +$124M | $62.26 | 125 |
| 2023 Q4 | 20.2M | $1.17B | +$18.7M | $57.76 | 111 |
| 2023 Q3 | 19.9M | $934M | +$42.9M | $46.98 | 90 |
| 2023 Q2 | 19.1M | $849M | +$223M | $44.40 | 89 |
| 2023 Q1 | 14.6M | $310M | +$77.1M | $21.19 | 45 |
| 2022 Q4 | 10.8M | $215M | +$202M | $19.89 | 30 |